Calkins
Transcription
Calkins
Case Studies Hugh Calkins, MD Case Presentations Hugh Calkins MD Case History #1 • Patient J.S., male, 56 yrs • Paroxysmal atrial fibrillation – 3 times each day, severe sx • PMH: Diabetes, hypertension, sleep apnea syndrome • Echo: mild LVH nl LV function • Meds: Lisinopril, insulin Toprol Case History #1 What Antithrombotic Strategy Would You Suggest? A) B) C) D) E) F) G) H) I) Aspirin 80 mg per day Aspirin 325 mg per day Coumadin INR 2 – 3.5 Coumadin INR 1.5-2.5 Pradaxa 150 mg bid Pradaxa 75 mg bid Xarelto 20 mg per day Xarelto 15 mg per day Watchman Device Case History #1 What Treatment Would You Suggest? A) Catheter ablation B) Flecainide C) Dronedarone D) Amiodarone E) AV node ablation and PPM Case History #1 (continued) AF recurs despite dronedarone What Treatment Would You Suggest? A) B) C) D) E) Catheter ablation Flecainide Tikosyn Amiodarone AV node ablation and PPM Case History #1 (continued) f/u appt 3 months post AF ablation – pt in afib What Treatment Would You Suggest? A) B) C) D) E) Repeat Catheter ablation MiniMaze procedure Cardioversion Amiodarone AV node ablation and PPM Case History #1 (continued) f/u appt 6 months post AF ablation – pt in reports 1 episode of AF each month lasting 20 minutes What Treatment Would You Suggest? A) B) C) D) E) F) Repeat Catheter ablation MiniMaze procedure Cardioversion Dronedarone AV node ablation and PPM Clinical follow-up Case History #2 • Patient D.B., male, 69 yrs • Paroxysmal atrial fibrillation – 1 episode every three months for 15 minutes • PMH: no prior medical problems • Echo: nl LV function • Meds:none Case History #2 What Antithrombotic Strategy Would You Suggest? A) B) C) D) E) F) G) H) I) Aspirin 80 mg per day Aspirin 325 mg per day Coumadin INR 2 – 3.5 Coumadin INR 1.5-2.5 Pradaxa 150 mg bid Pradaxa 75 mg bid Xarelto 20 mg per day Xarelto 15 mg per day Watchman Device Case History #2 What Treatment Would You Suggest? A) Catheter ablation B) Flecainide C) Dronedarone D) Amiodarone E) AV node ablation and PPM Case History #2 (continued) AF recurs on one occasion despite Flecainide What Treatment Would You Suggest? A) B) C) D) E) Catheter ablation Continue Flecainide Tikosyn Amiodarone AV node ablation and PPM Case History #2 (continued) • Catheter ablation is performed. • Two weeks later the patient develops an incessant atrial tachycardia with rapid response. • The atrial tachycardia recurs despite cardioversion. • The atrial tachycardia recurs despite repeat cardioversion on amiodarone. • A repeat echo reveals an EF of 30% Case History #2 (continued) What Treatment Would You Suggest? A) B) C) D) E) Repeat Catheter ablation MiniMaze procedure Cardioversion Amiodarone AV node ablation and PPM Case 2: 12-lead ECG at EPS Intracardiac Tracings 390 390 390 390 390 Entrainment Pacing from RA Isthmus Activation Mapping with Image Integration Site with Mid Diastolic Potential (MDP) RF on Termination during Entrainment Pacing at Site with MDP RF on Termination during First RF Application RF on Substrate Ablation after Termination Case History #2 What would you do next? 1) Terminate the procedure 2) Test for inducibility, if non inducible stop the procedure 3) Test for inducibility. If noninducible reisolate the PVs if not isolated. 4) Test for inducibility. If noninducible reisolate the PVs even if they are currently isolated based on lasso mapping. of 30% End point 1: substrate elimination End point 2: non-inducibility Mechanism: small reentry probably related to PV ablation lesions Discussion • Left atrial flutters occur following 5% of AF ablation procedures. • Left atrial flutter post AFib ablation can result from microreentry in close proximity to the pulmonary veins which is amenable to focal ablation or can be due to macroreentry. • The optimal approach to mapping is uncertain. • A variety of strategies for ablation have been used. Thank You
Similar documents
Ideopathic Ventricular Tachycardia: The Usual and Unusual
• 3-D electroanatomic mapping system, non-contact mapping system • Non-reentrant mechanism, entrainment won’t work • Terminates with adenosine (helps differentiate from ARVC VT) • If no early focus...
More information